FOLD — Amicus Therapeutics Share News
0.000.00%
Last trade - 00:00- $4.55bn
- $4.65bn
- $634.21m
Amicus Therapeutics up as UK health agency approves muscle disorder therapy
Brief: Amicus Therapeutics Announces Approval And Launch Of New Pompe Disease Therapy In The United Kingdom
Amicus Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Amicus Therapeutics Q2 Revenue USD 94.5 Million Vs. IBES Estimate USD 89.9 Million
Amicus Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Amicus Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Amicus Therapeutics Announces Approval, Launch Of New Pompe Disease Therapy In The European Union
Amicus Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Amicus Therapeutics Q1 revenue USD 86.3 million
Brief: Amicus Therapeutics Announces Q1 2023 Financial Results And Corporate Updates
Amicus Therapeutics Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Amicus Therapeutics Receives Positive CHMP Opinion For Opfolda® (Miglustat) For Late-Onset Pompe Disease
Brief: EMA Says Application For Marketing Authorisation For The Advanced Therapy Medicinal Product Lumevoq Withdrawn
Brief: Amicus Therapeutics Enters Into Supply And Manufacturing Services Agreement With Wuxi
Brief: Amicus Therapeutics Announces European Commission Approval For Pombiliti™ In Patients With Late-Onset Pompe Disease
European Commission approves Amicus muscle disorder therapy
Brief: Amicus Therapeutics Announces Full-Year 2022 Financial Results And Corporate Updates
Amicus Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Amicus Therapeutics Provides FY Revenue Growth Outlook